METASTATIC RENAL CELL CARCINOMA

This adverse event was reported 1832 times

These drugs are most commonly taken by patients reporting METASTATIC RENAL CELL CARCINOMA:

# Drug Count
0 SUNITINIB MALATE 762
1 AXITINIB 210
2 PAZOPANIB HYDROCHLORIDE 175
3 EVEROLIMUS 143
4 SORAFENIB 104
5 OMEPRAZOLE MAGNESIUM 101
6 CABOZANTINIB 96
7 AMLODIPINE 95
8 FUROSEMIDE 90
9 ASPIRIN 80
See all common drugs associated with METASTATIC RENAL CELL CARCINOMA

METASTATIC RENAL CELL CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SUNITINIB MALATE 762 0.0195
1 TEMSIROLIMUS 78 0.0173
2 AXITINIB 210 0.0107
3 PAZOPANIB HYDROCHLORIDE 175 0.0065
4 ALDESLEUKIN 8 0.0063
5 SORAFENIB 104 0.0050
6 EVEROLIMUS 143 0.0029
7 EVEROLIMUS TABLETS 46 0.0027
8 ERGOCALCIFEROL 74 0.0025
9 CABOZANTINIB 96 0.0020
See all drugs enriched for association with METASTATIC RENAL CELL CARCINOMA

METASTATIC RENAL CELL CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Lymphocyte Growth Factor [EPC] 8 0.0063
1 Provitamin D2 Compound [EPC] 74 0.0025
2 Cannabinoid [EPC] 8 0.0010
3 Programmed Death Receptor-1 Blocking Antibody [EPC] 92 0.0009
4 Kinase Inhibitor [EPC] 459 0.0008
5 Interferon gamma [EPC] 1 0.0007
6 Calcitonin [EPC] 2 0.0006
7 Bismuth [EPC] 3 0.0005
8 Guanylate Cyclase-C Agonist [EPC] 1 0.0005
9 Non-Standardized Fungal Allergenic Extract [EPC] 1 0.0005
See all drug classes enriched for association with METASTATIC RENAL CELL CARCINOMA